Diagnostic Significance of CD10 Marker to Differentiate Colorectal Adenocarcinoma from Adenomatous Polyp: A Pathological Correlation

Overview

Journal Caspian J Intern Med

Specialty General Medicine

Date 2024 May 29

PMID 38807719

Authors

Ghasem Dehini

Hossein Ghorbani

Soraya Khafri

Javad Shokri Shirvani

Akramossadat Hosseini

Sahar Sadr Mohararpur

Tina Rouhi

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer could be developed from adenomatous polyp. The study aimed to evaluate the diagnostic significance of stromal and epithelial CD10 (Neprilysin) expression in patients with colorectal adenocarcinoma and adenomatous polyps.

Methods: This cross-sectional study was conducted on 141 patients with colorectal adenocarcinoma and adenomatous polyps referred to Ayatollah Rouhani Hospital from March 2020 to March 2021. Differential diagnoses of colorectal adenocarcinoma and adenomatous polyps were made colonoscopically, and then samples were taken from the lesions. The pathologists confirmed the final diagnosis as colorectal adenocarcinoma, high-grade or low-grade adenomatous polyps. The stromal and epithelial CD10 expression was evaluated by immunohistochemistry. The data was analyzed by SPSS 22 software (p<0.05).

Results: Sixty-five (46.1%) of the cases were low-grade polyps that were included positive (4 cases; 6.20%) and negative (61 cases; 93.80%) CD10 expression (P=0.001), also 76 (53.9%) of them were either high-grade polyps (21 cases) or adenocarcinomas (21 cases). Also, epithelial CD10 expression was significantly higher in the well-differentiated adenocarcinoma (38 cases) group than moderate (13 cases) and poor (4 cases) groups (P =0.001). Moreover, the CD10 expression level in the adenomatous polyps (10 positive cases and 76 negative cases) was correlated with the degree of dysplasia (P = 0.001) and the presence of tumor invasion (8 positive cases and 133 negative cases) (P = 0.001).

Conclusion: The CD10 expression is associated with an increased degree of dysplasia and the presence of tumor invasion in patients with pre-neoplastic lesions and colorectal adenocarcinoma.

References

Swiderska M, Choromanska B, Dabrowska E, Konarzewska-Duchnowska E, Choromanska K, Szczurko G . The diagnostics of colorectal cancer. Contemp Oncol (Pozn). 2014; 18(1):1-6. PMC: 4037991. DOI: 10.5114/wo.2013.39995. View

Ogawa H, Iwaya K, Izumi M, Kuroda M, Serizawa H, Koyanagi Y . Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol. 2002; 33(8):806-11. DOI: 10.1053/hupa.2002.125773. View

Muller M, Ibrahim A, Arends M . Molecular pathological classification of colorectal cancer. Virchows Arch. 2016; 469(2):125-34. PMC: 4978761. DOI: 10.1007/s00428-016-1956-3. View

Mishra D, Singh S, Narayan G . Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis. Mol Biol Int. 2016; 2016:4328697. PMC: 5124668. DOI: 10.1155/2016/4328697. View

Ibrahim W . Comparison of stromal CD10 expression in benign, borderline, and malignant phyllodes tumors among Egyptian female patients. Indian J Pathol Microbiol. 2012; 54(4):741-4. DOI: 10.4103/0377-4929.91511. View

Jass J . Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007; 50(1):113-30. DOI: 10.1111/j.1365-2559.2006.02549.x. View

Gabal S, Salem M, Mostafa R, Abdelsalam S . Role of CD10 Marker in Differentiating Malignant Thyroid Neoplasms from Benign Thyroid Lesions (Immunohistochemical & Histopathological Study). Open Access Maced J Med Sci. 2019; 6(12):2295-2300. PMC: 6311489. DOI: 10.3889/oamjms.2018.456. View

Torring M, Frydenberg M, Hansen R, Olesen F, Vedsted P . Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer. 2013; 49(9):2187-98. DOI: 10.1016/j.ejca.2013.01.025. View

Iwase T, Kushima R, Mukaisho K, Mitsufuji S, Okanoue T, Hattori T . Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathol Res Pract. 2005; 201(2):83-91. DOI: 10.1016/j.prp.2004.09.016. View

10.

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

11.

Mizutani N, Abe M, Kajino K, Matsuoka S . A New CD10 Antibody Inhibits the Growth of Malignant Mesothelioma. Monoclon Antib Immunodiagn Immunother. 2021; 40(1):21-27. PMC: 7910416. DOI: 10.1089/mab.2020.0033. View

12.

Liebl M, Hofmann T . The Role of p53 Signaling in Colorectal Cancer. Cancers (Basel). 2021; 13(9). PMC: 8125348. DOI: 10.3390/cancers13092125. View

13.

Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R . CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology. 2004; 45(5):460-7. DOI: 10.1111/j.1365-2559.2004.01982.x. View

14.

Rabeneck L, Paszat L, Saskin R, Stukel T . Association between colonoscopy rates and colorectal cancer mortality. Am J Gastroenterol. 2010; 105(7):1627-32. DOI: 10.1038/ajg.2010.83. View

15.

Fujita S, Yamamoto S, Akasu T, Moriya Y, Taniguchi H, Shimoda T . Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis. Anticancer Res. 2007; 27(5A):3307-11. View

16.

Yang T, Li X, Farrington S, Dunlop M, Campbell H, Timofeeva M . A Systematic Analysis of Interactions between Environmental Risk Factors and Genetic Variation in Susceptibility to Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020; 29(6):1145-1153. PMC: 7311198. DOI: 10.1158/1055-9965.EPI-19-1328. View

17.

Siegel R, Torre L, Soerjomataram I, Hayes R, Bray F, Weber T . Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019; 68(12):2179-2185. DOI: 10.1136/gutjnl-2019-319511. View

18.

Kolligs F . Diagnostics and Epidemiology of Colorectal Cancer. Visc Med. 2016; 32(3):158-64. PMC: 4945785. DOI: 10.1159/000446488. View

19.

Khanh D, Mekata E, Mukaisho K, Sugihara H, Shimizu T, Shiomi H . Prognostic role of CD10⁺ myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci. 2011; 102(9):1724-33. PMC: 11158074. DOI: 10.1111/j.1349-7006.2011.01987.x. View

20.

Jang T, Park J, Lee J . The Expression of CD10 and CD15 Is Progressively Increased during Colorectal Cancer Development. Korean J Pathol. 2013; 47(4):340-7. PMC: 3759633. DOI: 10.4132/KoreanJPathol.2013.47.4.340. View